HOLX / Hologic, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Refinancing Amendment No. 4 and Amendment to Pledge and Security Agreement, dated as of July 15, 2025, among Hologic, Inc., the subsidiaries of Hologic, Inc. party thereto, the lenders and issuing banks party thereto, and Bank of America, N.A., as administrative agent and as collateral agent.

ex101-hologicrefinancing Exhibit 10.1 Execution Version REFINANCING AMENDMENT NO. 4 AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT, dated as of July 15, 2025 (this “Amendment”), among HOLOGIC, INC., a Delaware corporation (the “Company”), HOLOGIC GGO 4 LTD. (the “UK Borrower”), the other Loan Parties party hereto, the 2025 Refinancing Term Lenders (as defined below), the 2025 Refinancing Revolving

Hologic, Inc. and Anne M. Liddy dated April 4, 2025

Exhibit 10.2 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Anne M. Liddy (the "Executive"), dated as of April 4, 2025. WHEREAS, the Executive is being promoted to General Counsel of the Company effective May 1, 2025; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it

Hologic Announces Financial Results for Third Quarter of Fiscal 2025 – Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains o

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2025 – Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – MARLBOROUGH, Mass. (July 30, 2025) – Hologic, Inc. (Nasdaq: HOLX) annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 HOLOGIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Refinancing Amendment No. 4 and Amendment to Pledge and Security Agreement, dated as of July 15, 2025, among Hologic, Inc., the subsidiaries of Hologic, Inc. party thereto, the lenders and issuing banks party thereto, and Bank of America, N.A., as administrative agent and as collateral agent.

EX-10.1 Exhibit 10.1 Execution Version REFINANCING AMENDMENT NO. 4 AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT, dated as of July 15, 2025 (this “Amendment”), among HOLOGIC, INC., a Delaware corporation (the “Company”), HOLOGIC GGO 4 LTD. (the “UK Borrower”), the other Loan Parties party hereto, the 2025 Refinancing Term Lenders (as defined below), the 2025 Refinancing Revolving Credit Lenders (

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Hologic, Inc. Conflict Minerals Report

Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024 (the Reporting Period). Rule 13p-1 requires disclosure of cer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification No.) 250 Campus Drive Marlborough, Massachusetts 01752 (Address of princi

everance and Change of Control Agreement dated January 17, 2025 by and between Mark Horvath and Hologic, Inc. (1)

Exhibit 10.1 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Mark Horvath (the "Executive"), dated as of January 17, 2025. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests of

eventh Supplemental Indenture dated as of March 12, 2025 among Hologic, Inc., the Subsidiary Guarantor Party Hereto and Comp

Exhibit 4.1 SEVENTH SUPPLEMENTAL INDENTURE dated as of March 12, 2025 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as Trustee 4.625% Senior Notes due 2028 This SEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), entered into as of March 12, 2025, among Hologic, Inc., a Delaware

ure dated as of March 12, 2025 among Hologic, Inc., the Su

Exhibit 4.2 THIRD SUPPLEMENTAL INDENTURE dated as of March 12, 2025 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as Trustee 3.250% Senior Notes due 2029 This THIRD SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), entered into as of March 12, 2025, among Hologic, Inc., a Delaware corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, IN

ransition Agreement dated January 10, 2025 by and between Hologic, Inc. and Erik S. Anderson (1)

Exhibit 10.2 TRANSITION AGREEMENT AGREEMENT entered into as of the 10th day of January, 2025 by and between Hologic, Inc., a Delaware corporation with its principal place of business at 250 Campus Drive, Massachusetts 01752 (the “Company”), and Erik S. Anderson, an individual having his principal residence in Eden Prairie, Minnesota (the “Executive”). WHEREAS, the Executive currently serves as Div

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number) (

Hologic Announces Financial Results for Second Quarter of Fiscal 2025 – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2025 – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – MARLBOROUGH, Mass. (May 1, 2025) – Hologic, Inc. (Nasdaq: HOLX) ann

Wayde McMillan Elected to Hologic Board of Directors

Exhibit 99.1 Wayde McMillan Elected to Hologic Board of Directors Marlborough, Mass., April 4, 2025 – Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025. Mr. McMillan has served as the Chief Financial Officer of Solv

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

ransition Letter Agreement between Hologic, Inc. and John M. Griffin dated March 3, 2025 (1)

Exhibit 10.1 March 3, 2025 John M. Griffin 250 Campus Drive Marlborough, MA 01752 Dear John, This letter agreement (this “Agreement”) outlines your retirement from Hologic, Inc. (the “Company”) and certain transition services you have agreed to provide to the Company. As previously discussed, your final date in your current position as General Counsel of the Company will be May 1, 2025 (the “Trans

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

false000085973700008597372025-02-262025-02-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

Hologic Announces Financial Results for First Quarter of Fiscal 2025 – Company Reports GAAP Diluted EPS of $0.87; Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Revenue of $1,021.8 Million Increases 0.9%; Constant Currency Growth of 1.0% I

Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2025 – Company Reports GAAP Diluted EPS of $0.87; Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Revenue of $1,021.8 Million Increases 0.9%; Constant Currency Growth of 1.0% In-Line with Guidance – – Company Lowers Full-Year Guidance for GAAP EPS, Maintains Guidance for Non-GAAP EPS - MARLBOROUGH, Mass. (Februa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )                     ☑     Filed by the Registrant      ☐     Filed by a Party other than the Registrant                       Check the appropriate box;  ☐     Preliminary Proxy Statement  ☐     Conf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant Check the appropriate box; ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025 – Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance – – GAAP and Non-GAAP EPS Expected to be Near High

Exhibit 99.1 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025 – Revenue of $1,021.8 Million Grows 0.9% - - Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance – – GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges – MARLBOROUGH, Mass. (January 12, 2025) – Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results f

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2025 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numbe

Martin Madaus Elected to Hologic Board of Directors

Exhibit 99.1 Martin Madaus Elected to Hologic Board of Directors Marlborough, Mass., December 9, 2024 – Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024. Dr. Mada

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Subsidiaries of Hologic

Exhibit 21.1 Subsidiaries of Hologic* Jurisdiction of Incorporation or Organization Acessa Health Inc. Delaware Beijing Hologic Technology Co., Ltd. China Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. Portugal Bioptics, Inc. Arizona Biotheranostics, Inc. Delaware Bolder Surgical Holdings, Inc. Delaware Bolder Surgical, LLC Colorado Cytyc Corporation Delaware Cytyc Prenatal Products C

Subsidiary Guarantors Party Hereto and Computershare Trust Company, National Association, as Trustee

Exhibit 4.6 SECOND SUPPLEMENTAL INDENTURE dated as of July 25, 2024 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Computershare Trust Company, N.A., as Trustee 3.250% Senior Notes due 2029 This SECOND SUPPLEMENTAL INDENTURE (this "Supplemental Indenture"), entered into as of July 25, 2024, among Hologic, Inc., a Delaware corporation (the "Company"), Hologic Capital Holdings, Inc.,

hird Amendment to Lease dated May 15, 2024 by and between BH GRP TCAM

Exhibit 10.59 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Amendment") is made and entered into as of May 15, 2024 (the "Effective Date"), by and between BH GRP TCAM Owner LLC, a Delaware limited liabilit

and between BH GRP TCAM Owner LLC and Hologic, Inc. (3)

Exhibit 10.58 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this "Amendment") is made and entered into as of October 30, 2023 (the "Effective Date"), by and between BH GRP TCAM Owner LLC, a Delaware limited li

orm of RSU Grant Agreement

Exhibit 10.55 Notice of Grant of Restricted Stock Units and Restricted Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Participant Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as may be amended from time to time (the "Plan") Effective , you have been granted an award of restricted stock units ("RSUs") of Hologic, Inc. (the

everance and Change of Control Agreement dated September 19, 2024 by and between Diana De Walt and Hologic, Inc.

Exhibit 10.53 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Diana De Walt (the "Executive"), dated as of September 19, 2024. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests

ing Policy (as amended June 13, 2024)

Exhibit 19.0 HOLOGIC, INC. INSIDER TRADING POLICY (As Amended June 13, 2024) Introduction Hologic, Inc. (the "Company") has adopted this Policy to prevent violations of U.S. insider trading laws by Company employees, officers and directors and to avoid even the appearance of improper conduct by these persons. This Policy also applies to others, such as contractors or consultants who have access to

ixth Supplemental Indenture dated as of July 25, 2024 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Computershare Trust Company, N.A.

Exhibit 4.12 SIXTH SUPPLEMENTAL INDENTURE dated as of July 25, 2024 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Computershare Trust Company, N.A., as Trustee 4.625% Senior Notes due 2028 This SIXTH SUPPLEMENTAL INDENTURE (this "Supplemental Indenture"), entered into as of July 25, 2024, among Hologic, Inc., a Delaware corporation (the "Company"), Hologic Capital Holdings, Inc.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36

Form of Performance Stock Unit Award Agreement (

Exhibit 10.2 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Form of Performance Stock Unit Award Agreement (

Exhibit 10.3 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Form of Performance Stock Unit Award Agreement (ROIC) (adopted fiscal 2025)

Exhibit 10.1 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024 – Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024 – Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – MARLBOROUGH,

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Hologic Announces Financial Results for Third Quarter of Fiscal 2024 – Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Consta

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2024 – Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period – MARLBOROUGH, Mass. (July 29, 2024

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification Number) 250 Campus Drive Marlborough, Massachusetts 01752 (Address of pri

Hologic, Inc. Conflict Minerals Report

Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2023 to December 31, 2023 (the Reporting Period). Rule 13p-1 requires disclosure of cer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commiss

Severance and Change of Control Agreement dated January 9, 2024 by and between Peter Dunne and Hologic, Inc. (1)

Exhibit 10.2 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Peter Dunne (the "Executive"), dated as of January 9, 2024. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests of th

everance and Change of Control Agreement dated January

Exhibit 10.3 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Brandon Schnittker (the "Executive"), dated as of January 18, 2024. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interes

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, IN

Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Gr

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue M

ransition Agreement dated December 31, 2023 by and between Hologic, Inc. and Elisabeth (Lisa) Hellmann

Exhibit 10.1 TRANSITION AGREEMENT AGREEMENT entered into as of this 31st day of December, 2023 by and between Hologic, Inc., a Delaware corporation with its principal place of business at 250 Campus Drive, Massachusetts 01752 (the “Company”), and Elisabeth (Lisa) A. Hellmann, an individual having her principal residence in Del Mar, California (the “Executive”). WHEREAS, the Executive currently ser

Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Gr

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue M

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (I.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (

HOLX / Hologic, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01126-hologicinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Hologic Inc Title of Class of Securities: Common Stock CUSIP Number: 436440101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2024 HOLOGIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Hologic Announces Financial Results for First Quarter of Fiscal 2024

Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2024 – Revenue of $1,013.1 Million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98; All Exceed Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 5.2% in Constant Currency Against Four Fewer Selling Days Compared to the Prior Year Period – – Company Increases Full-Year Revenue and EPS Gu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant Check the appropriate box;  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule

COURTESY PDF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant Check the appropriate box; ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024

Exhibit 99.1 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024 – Revenue of $1,013.1 Million Exceeds Guidance – – 5.2% Organic Constant Currency Revenue Growth ex. COVID-19, also Exceeding Guidance – MARLBOROUGH, Mass.-(BUSINESS WIRE)-January 7, 2024-Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 30,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2024 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2023 HOLOGIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Director Stock Option Award Agreement Under 2008 Equity Incentive Plan

Exhibit 10.4 Notice of Grant of Stock Options And Option Agreement (Independent Director) Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Participant Name Plan: 2008 Equity Incentive Plan, as may be amended from time to time (the “Plan”) Effective GRANT DATE, you have been granted a Non-Qualified Stock Option (the “Option”) to buy SHARES GRANTED shares of Hologic, Inc. (the “Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36

Hologic, Inc. Amended and Restated Policy on Recoupment (Claw-back) of Incentive-based Compensation

Exhibit 97.1 HOLOGIC, INC. AMENDED AND RESTATED POLICY ON RECOUPMENT (CLAW-BACK) OF INCENTIVE-BASED COMPENSATION PART I. MANDATORY RECOUPMENT Recoupment of Incentive-Based Compensation It is the policy of Hologic, Inc. (“Hologic” or the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance of

Form of Independent Director Restricted Stock Unit Award Agreement Under 2008 Equity Incentive

Exhibit 10.7 Notice of Grant of Restricted Stock Units and Restricted Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 (Independent Director) Participant Name Plan: 2008 Equity Incentive Plan, as may be amended from time to time (the “Plan”) Effective GRANT DATE, you have been granted an award of SHARES GRANTED restricted stock units (“RSUs”) of Hologi

Subsidiaries of Hologic

Exhibit 21.1 Subsidiaries of Hologic* Jurisdiction of Incorporation or Organization Acessa Health Inc. Delaware Beijing Hologic Technology Co., Ltd. China Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. Portugal BioLucent, LLC Delaware Bioptics, Inc. Arizona Biotheranostics, Inc. Delaware Bolder Surgical Holdings, Inc. Delaware Bolder Surgical, LLC Colorado Cytyc Corporation Delaware C

Form of Performance Stock Unit Award Agreement (relative TSR) (adopted fiscal 2024)

EX-10.2 Exhibit 10.2 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number

2008 Equity Incentive Plan (adopted fiscal 2024)

EX-10.5 Exhibit 10.5 Notice of Grant of Stock Options And Option Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Participant Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as may be amended from time to time (the “Plan”) Effective GRANT DATE, you have been granted a Non-Qualified Stock Option (the “Option”) to buy SHARES GRANTED shares of Ho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 HOLOGIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number

2008 Equity Incentive Plan (ROIC) (adopted fiscal 2024)

EX-10.1 Exhibit 10.1 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number

Form of Performance Stock Unit Award Agreement (FCF) (adopted fiscal 2024)

EX-10.3 Exhibit 10.3 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number

Equity Incentive Plan (adopted fiscal 2024)

EX-10.4 Exhibit 10.4 Notice of Grant of Restricted Stock Units and Restricted Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Participant Name Plan: Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan, as may be amended from time to time (the “Plan”) Effective , you have been granted an award of restricted stock units (“RSUs”) of Hologic, In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023 – Revenue of $945.3 Million, GAAP Diluted EPS of $0.37, and Non-GAAP Diluted EPS of $0.89 – – Total Company Organic Revenue Growth excluding COVID-19 of 16.7% in constant currency – – Expect Broad Based Strong Performance in Fiscal 2024 – MARLBOROUGH, Mass.-(BUSINESS WIRE)-November 9, 2023-Hologic, Inc. (Nasdaq: HOL

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Nu

Nanaz Mohtashami Elected to Hologic Board of Directors

Exhibit 99.1 Nanaz Mohtashami Elected to Hologic Board of Directors MARLBOROUGH, Mass.-(BUSINESS WIRE)-September 22, 2023-Hologic, Inc. (Nasdaq: HOLX) announced today that Nanaz Mohtashami has been elected to the Company’s Board of Directors, effective September 20, 2023. Ms. Mohtashami was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective

everance and Change of Control Agreement dated July 20, 2023 by and between Essex D. Mitchell and Hologic, Inc.

Exhibit 10.3 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Essex D. Mitchell (the "Executive"), dated as of July 20, 2023. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests o

ange of Control Agreement dated July 20, 2023 by and between Erik S. Anderson and Hologic, Inc.

Exhibit 10.2 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Erik S. Anderson (the "Executive"), dated as of July 20, 2023. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests of

Amendment No. 1 to the Hologic, Inc. Amended and Restated Deferred Compensation Program (1)

Exhibit 10.1 THE HOLOGIC, INC. AMENDED AND RESTATED DEFERRED COMPENSATION PROGRAM Amended and Restated September 17, 2015 THE HOLOGIC, INC. AMENDED AND RESTATED DEFERRED COMPENSATION PROGRAM ARTICLE 1 - PURPOSE; EFFECTIVE DATE 1.1 Purpose. The purpose of this HOLOGIC, INC. AMENDED AND RESTATED DEFERRED COMPENSATION PROGRAM (hereinafter, the “Plan”) is to permit a select group of management or high

by and between Jennifer Schneiders and Hologic, Inc. (1)

Exhibit 10.4 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Jennifer Schneiders (the "Executive"), dated as of July 20, 2023. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best interests

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC.

Amended and Restated Employment Agreement between Jan Verstreken and Hologic dated June 14, 2023

Exhibit 10.5 HOLOGIC AMENDED AND RESTATED EMPLOYMENT AGREEMENT between Hologic Swiss Group GmbH, Baarerstrasse 52, 6300 Zug, Switzerland (hereinafter referred to as "Company") and Jan Verstreken, at the address on record with the Company (hereinafter referred to as "Employee") Hereinafter jointly referred to as "Parties" IT IS AGREED as follows: 1.FUNCTION 1.1The Company employs the Employee as Gr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Hologic Announces Financial Results for Third Quarter of Fiscal 2023

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2023 – Revenue of $984.4 Million, GAAP Diluted EPS of ($0.16), and Non-GAAP Diluted EPS of $0.93 – – Total Company Organic Revenue Growth excluding COVID-19 of 18.4% in constant currency - Each Business Grows Double-Digits – MARLBOROUGH, Mass.-(BUSINESS WIRE)-July 31, 2023-Hologic, Inc. (Nasdaq: HOLX) announced today the

Hologic, Inc. Conflict Minerals Report

EX-1.01 2 a2023conflictminerals-ex.htm EX-1.01 Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2022 to December 31, 2022 (the Reporting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification Number) 250 Campus Drive Marlborough, Massachusetts 01752 (Address of pri

Quarterly Report on Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Power of Attorney (included on the signature pages to this Registration Statement)

S-8 As filed with the Securities and Exchange Commission on May 2, 2023 Registration No.

Filing Fee Table

Exhibit 107 Form S-8 (Form Type) Hologic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per share Other 6,500,000(2) $84.03(3)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2023 HOLOGIC, INC. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number) (

Hologic Announces Financial Results for Second Quarter of Fiscal 2023

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2023 – Revenue of $1,026.5 Million, GAAP Diluted EPS of $0.87, and Non-GAAP Diluted EPS of $1.06 All Exceed Guidance – – Total Company Organic Revenue Growth excluding COVID-19 Exceeds 20%; Each Business Delivers Strong Performance – – Company Raises Fiscal 2023 Revenue and EPS Guidance – MARLBOROUGH, Mass.-(BUSINESS WIR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 17, 2023 HOLOGIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 17, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

Hologic Amended and Restated 2008 Equity Incentive Plan

Exhibit 10.1 HOLOGIC, INC. AMENDED AND RESTATED 2008 EQUITY INCENTIVE PLAN (amended as of March 9, 2023) 1.Purpose and Eligibility. The purpose of this Amended and Restated 2008 Equity Incentive Plan (the “Plan”) of HOLOGIC, INC., a Delaware corporation (the “Company”), is to provide stock options, stock issuances and other equity interests in the Company (each, an “Award”) to (a) employees, offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2023 HOLOGIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (

Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan

Exhibit 10.2 HOLOGIC, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The Hologic, Inc. 2012 Employee Stock Purchase Plan (the "Plan") is intended to provide a method whereby employees of Hologic, Inc. (the "Company") and participating subsidiaries will have an opportunity to acquire a proprietary interest in the Company through the purchase of shares of the Company's $.01

HOLX / Hologic, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01088-hologicinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Hologic Inc. Title of Class of Securities: Common Stock CUSIP Number: 436440101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule

Hologic Announces Financial Results for First Quarter of Fiscal 2023

EX-99.1 2 a53296357ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2023 – Revenue of $1,074 Million, GAAP Diluted EPS of $0.75, and Non-GAAP Diluted EPS of $1.07 All Exceed Guidance – – Broad-Based Organic Revenue Growth ex. COVID-19; Diagnostics and Surgical Grow Double-Digits in Constant Currency – – Company Increases Full-Year Revenue and EPS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant Check the appropriate box;  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule

COURTESY PDF

Notice of Annual Meeting of Stockholders and Proxy Statement 2023 Thursday | March 9, 2023 | 8:00am ETDear Fellow Stockholders: Fiscal 2022 was another dynamic year for Hologic.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant Check the appropriate box;  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023

EX-99.1 2 a53178442ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023 – Revenue of $1,074.2 Million Exceeds Guidance – – 15.8% Organic Constant Currency Growth in Diagnostics ex-COVID – – 24.5% Organic Constant Currency Growth in Molecular Diagnostics ex-COVID – – 14.7% Organic Constant Currency Growth in Surgical – MARLBOROUGH, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2023 HOLOGIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2023 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Stacey D. Stewart Elected to Hologic Board of Directors

Exhibit 99.1 Stacey D. Stewart Elected to Hologic Board of Directors MARLBOROUGH, Mass.-(BUSINESS WIRE)-December 9, 2022-Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company?s Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023. Ms. Stewart has served as President a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 24, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36

As filed with the Securities and Exchange Commission on November 15, 2022

Table of Contents As filed with the Securities and Exchange Commission on November 15, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Hologic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Type Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward F

Form of Change of Control Agreement (3)

CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between Hologic, Inc.

Subsidiaries of Hologic.

Exhibit 21.1 Subsidiaries of Hologic* Jurisdiction of Incorporation or Organization Acessa Health Inc. Delaware Beijing Hologic Technology Co., Ltd. China Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. Portugal BioLucent, LLC Delaware Bioptics, Inc. Arizona Biotheranostics, Inc. Delaware Bolder Surgical Holdings, Inc. Delaware Bolder Surgical, LLC Colorado Cytyc Corporation Delaware C

Form of Senior Vice President Severance Agreement (2)

SENIOR VICE PRESIDENT SEVERANCE AGREEMENT THIS AGREEMENT made as of the day of , 20, by and between Hologic, Inc.

Form of Restricted Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Outside US) (adopted fiscal 2017)

Notice of Grant of Restricted Stock Units and Restricted Stock Unit Award Agreement Hologic, Inc.

Form of Division President Severance Agreement (1)

DIVISION PRESIDENT SEVERANCE AGREEMENT THIS AGREEMENT made as of the day of , 20, by and between Hologic, Inc.

Refinancing Amendment No. 3, dated as of August 22, 2022, to the Amended and Restated Credit and Guaranty Agreement dated as of October 3, 2017, as amended

Execution Version AMENDMENT NO. 3 (this ?Third Amendment?) dated as of August 22, 2022, to the Amended and Restated Credit and Guaranty Agreement dated as of October 3, 2017 (as amended by that certain Refinancing Amendment No. 1, dated as of December 17, 2018, as amended by that certain Refinancing Amendment No. 2, dated as of September 27, 2021, and as further amended, restated, supplemented or

Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of Wilmington Trust Company as trustee under the Indenture

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST COMPANY (Exact name of Trustee as specified in its charter) Delaware 51-0055023 (Jurisdiction of inc

Transition Agreement by and between Sean S. Daugherty and Hologic, Inc. dated October 1, 2022

TRANSITION AGREEMENT AGREEMENT entered into as of this 1st day of October 2022 by and between Hologic, Inc.

Form of Stock Option Award Agreement Under 2008 Equity Incentive Plan (Outside US) (adopted fiscal 2017)

Notice of Grant of Stock Options And Option Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Participant Name Plan: Hologic, Inc. 2008 Equity Incentive Plan, as may be amended from time to time (the ?Plan?) Effective GRANT DATE, you have been granted a Non-Qualified Stock Option (the ?Option?) to buy SHARES GRANTED shares of Hologic, Inc. (the ?Company?) common stock a

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2023)

Exhibit 10.6 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR – Outside US) (adopted fiscal 2023)

Exhibit 10.5 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC) (adopted fiscal 2023)

EXHIBIT 10.1 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC – Outside US) (adopted fiscal 2023)

Exhibit 10.4 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR) (adopted fiscal 2023)

EXHIBIT 10.2 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow) (adopted fiscal 2023)

Exhibit 10.3 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022 ? Revenue of $953 Million, GAAP Diluted EPS of $0.47, and Non-GAAP Diluted EPS of $0.82 All Exceed Expectations ? ? Global Organic Molecular Diagnostics Revenue Grows 17% in Constant Currency, ex-COVID-19 ? ? Fiscal 2023 Financial Guidance Anticipates Strong Growth in All Core Businesses ? MARLBOROUGH, Mass.-(BUSINE

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 22, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Nu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 29, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 25, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Hologic Announces Financial Results for Third Quarter of Fiscal 2022

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2022 ? Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations ? ? Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency ? ? Company Again Increases Full-Year Revenue and EPS Guidance ? MARLBOROUGH, Mass.-(BUSINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification Number) 250 Campus Drive Marlborough, Massachusetts 01752 (Address of pri

Hologic, Inc. Conflict Minerals Report

Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2021 to December 31, 2021 (the Reporting Period). Rule 13p-1 requires disclosure of cer

Hologic Announces Financial Results for Second Quarter of Fiscal 2022

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2022 ? Revenue of $1.436 Billion, GAAP Diluted EPS of $1.80, and Non-GAAP Diluted EPS of $2.07 All Significantly Ahead of Expectations ? ? Company Again Increases Full-Year Revenue and EPS Guidance ? MARLBOROUGH, Mass.-(BUSINESS WIRE)-April 27, 2022-Hologic, Inc. (Nasdaq: HOLX) announced today the Company?s financial res

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 26, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, IN

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

HOLX / Hologic, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Hologic Inc. Title of Class of Securities: Common Stock CUSIP Number: 436440101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 25, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

Hologic Announces Financial Results for First Quarter of Fiscal 2022

Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2022 ? Revenue of $1.471 Billion, GAAP Diluted EPS of $1.95, and Non-GAAP Diluted EPS of $2.17 All Significantly Exceed Expectations ? ? Broad-Based Organic Revenue Growth of 9% Excluding COVID; Each Division Above 8% Global Growth Excluding COVID ? ? Company Significantly Increases Full-Year Revenue and EPS Guidance ? MA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Definitive Proxy Statement

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? Filed by the Registrant ? ? ?? ? ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, For Use of the Commission Only (

COURTESY PDF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2022 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numbe

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022

Exhibit 99.1 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022 ? Revenue of $1,471.1 Million Significantly Exceeds Guidance ? ? Organic Revenue Grows 9% Excluding COVID-19 Benefits ? ? More than 8% Global Organic Growth in All Businesses: Breast, Surgical, Skeletal and Diagnostics ex-COVID ? MARLBOROUGH, Mass.-(BUSINESS WIRE)-January 9, 2022-Hologic, Inc. (Nasdaq: HOLX

Subsidiaries of Hologic.

Exhibit 21.1 Subsidiaries of Hologic* Jurisdiction of Incorporation or Organization Acessa Health Inc. Delaware Beijing Hologic Technology Co., Ltd. China Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. Portugal BioLucent, LLC Delaware Bioptics, Inc. Arizona Biotheranostics, Inc. Delaware Cytyc Corporation Delaware Cytyc Prenatal Products Corp. Delaware Cytyc Surgical Products, LLC Mas

Fifth Supplemental Indenture dated as of May 18, 2021 among Hologic, Inc., the Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee

FIFTH SUPPLEMENTAL INDENTURE dated as of May 18, 2021 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee 4.625% Senior Notes due 2028 This FIFTH SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), entered into as of May 18, 2021, among HOLOGIC, INC., a Delaware corporation (the ?Company?), Biotheranostics Inc., a Delaware corporati

Third Supplemental Indenture dated as of January 8, 2019 among Hologic, Inc., the Subsidiary Guarantors Party Hereto and Wells Fargo Bank, National Association, as Trustee

THIRD SUPPLEMENTAL INDENTURE dated as of January 8, 2019 among Hologic, Inc., The Subsidiary Guarantors Party Hereto and Wells Fargo Bank, National Association, as Trustee 4.625% Senior Notes due 2028 THIS THIRD SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), entered into as of January 8, 2019, among HOLOGIC, INC., a Delaware corporation (the ?Company?), Focal Therapeutics, Inc., a Delawar

at Crewe Road, Wythenshawe in the City of Manchester between the Council of the City of Manchester and V.G. Instruments Group Limited dated February 8, 1988 (

CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL, AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 25, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36

First Supplemental Indenture dated as of May 18, 2021 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee

FIRST SUPPLEMENTAL INDENTURE dated as of May 18, 2021 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee 3.250% Senior Notes due 2029 This FIRST SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), entered into as of May 18, 2021, among HOLOGIC, INC., a Delaware corporation (the ?Company?), Biotheranostics Inc., a Delaware corporati

Fourth Supplemental Indenture dated as of March 14, 2019 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee

FOURTH SUPPLEMENTAL INDENTURE dated as of March 14, 2019 among Hologic, Inc., The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association, as Trustee 4.625% Senior Notes due 2028 THIS FOURTH SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), entered into as of March 14, 2019, among HOLOGIC, INC., a Delaware corporation (the ?Company?), Cynosure, LLC, a Delaware limited li

Second Supplemental Indenture dated as of November 9, 2018 among Hologic, Inc., The Subsidiary Guarantor Parties Hereto and Wells Fargo Bank, National Association, as Trustee

Execution Version SECOND SUPPLEMENTAL INDENTURE dated as of November 9, 2018 among Hologic, Inc.

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2022)

Exhibit 10.6 Hologic, Inc. Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC – Outside US) (adopted fiscal 2022)

Exhibit 10.4 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow) (adopted fiscal 2022)

Exhibit 10.3 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR) (adopted fiscal 2022)

Exhibit 10.2 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR – Outside US) (adopted fiscal 2022)

Exhibit 10.5 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC) (adopted fiscal 2022)

Exhibit 10.1 Hologic, Inc. Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the ?Plan?) Effective GRANT DATE (the ?Grant Date?), you (the ?Grantee?) have been granted an award of a target number of SHARES GRANTED performance stock units

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021 ? Revenue of $1.317 Billion Exceeds Expectations ? ? Company Posts GAAP Diluted EPS of $1.28, Non-GAAP Diluted EPS of $1.61 ? ? Financial Guidance for Fiscal 2022 Anticipates Solid Growth in Core Women?s Health Businesses and Continued Contributions to COVID-19 Fight ? MARLBOROUGH, Mass.-(BUSINESS WIRE)-November 1,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Numb

Refinancing Amendment No. 2, dated as of September 27, 2021, to the Amended and Restated Credit and Guaranty Agreement dated as of October 3, 2017, as amended.

Exhibit 10.1 EXECUTION VERSION REFINANCING AMENDMENT NO. 2 (this ?Second Amendment?) dated as of September 27, 2021, to the Amended and Restated Credit and Guaranty Agreement dated as of October 3, 2017 (as amended by that certain Refinancing Amendment No. 1, dated as of December 17, 2018, and as may be further amended, restated, supplemented or otherwise modified from time to time prior to the da

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 26, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Hologic, Inc. dated July 2, 2021

Exhibit 10.2 TRANSITION AGREEMENT AGREEMENT entered into as of this 2nd day of July, 2021 by and between Hologic, Inc., a Delaware corporation with its principal place of business at 250 Campus Drive, Massachusetts 01752 (the ?Company?), and Allison P. Bebo, an individual having her principal residence in Stowe, Vermont (the ?Executive?). WHEREAS, the Executive currently serves as Senior Vice Pres

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Hologic Announces Financial Results for Third Quarter of Fiscal 2021

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2021 ? Revenue of $1.168 Billion Increases 42.0%, 37.8% in Constant Currency ? ? Organic Revenue Increases 38.4%, 34.2% in Constant Currency ? ? Company Posts GAAP Diluted EPS of $1.04, Non-GAAP Diluted EPS of $1.33 ? MARLBOROUGH, Mass.-(BUSINESS WIRE)-July 28, 2021-Hologic, Inc. (Nasdaq: HOLX) announced today the Company

Severance and Change of Control Agreement dated June 28, 2021 by and between Elisabeth (Lisa) Hellmann and Hologic, Inc.

Exhibit 10.1 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Elisabeth (Lisa) A. Hellmann (the "Executive"), dated as of June 28, 2021. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Board"), has determined that it is in the best

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification Number) 250 Campus Drive Marlborough, Massachusetts 01752 (Address of pri

EX-1.01

EX-1.01 2 a2021conflictminerals-ex.htm EX-1.01 Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2020 to December 31, 2020 (the Reporting

Hologic Announces Financial Results for Second Quarter of Fiscal 2021

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2021 - Revenue of $1.538 Billion Increases 103.4%, 98.7% in Constant Currency - - Organic Revenue Increases 104.7%, 100.0% in Constant Currency - - Company Posts GAAP Diluted EPS of $2.38, Non-GAAP Diluted EPS of $2.59 - MARLBOROUGH, Mass.-(BUSINESS WIRE)-April 28, 2021-Hologic, Inc. (Nasdaq: HOLX) announced today the Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 27, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, IN

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million — Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Cap

Exhibit 99.1 Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million ? Transaction Will Accelerate Global Growth of Mobidiag?s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time ? MARLBOROUGH, Mass., April 08, 2021 ? Hologic, Inc. (Nasdaq: HOLX), a global leader in women?s health,

Share Purchase Agreement, dated as of April 8, 2021, by and among Hologic, Inc. and certain sellers listed therein.

Exhibit 2.1 EXECUTION COPY Share Purchase Agreement between Sellers and Hologic, Inc. regarding Mobidiag Oy 8 April 2021 Table of Contents 2. Definitions 2 3. Sale and purchase 9 4. Purchase Price 10 4.1 Amount and method of payment 10 4.2 Leakage 10 4.3 Allocation 11 5. Condition 12 5.1 Condition precedent of Seller 12 5.2 Condition precedent of Buyer 12 5.3 Responsibility for satisfaction 13 5.4

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 11, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Hologic Inc. Title of Class of Securities: Common Stock CUSIP Number: 436440101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

Financial Statements and Exhibits, Results of Operations and Financial Condition - HOLOGIC, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Amended Contract of Employment between Jan Verstreken and Hologic dated December 11, 2020

EX-10.1 2 ex101verstreken-ukcontract.htm EX-10.1 Ex. 10.1 AMENDED CONTRACT OF EMPLOYMENT Statement of Main Terms and Conditions of Employment, pursuant to the Employment Rights Act 1996 PARTIES TO THE CONTRACT OF EMPLOYMENT Employer: Hologic Limited, Heron House, Oaks Business Park, Crewe Road, Wythenshawe, Manchester M23 9HZ. Hereinafter called “the Company” Employee: Jan Verstreken JOB TITLE You

Hologic Announces Financial Results for First Quarter of Fiscal 2021

EX-99.1 2 a52368387ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Financial Results for First Quarter of Fiscal 2021 – Revenue of $1.61 Billion Increases 89.3%, 86.5% in Constant Currency – – Organic Revenue Increases 107.0%, 104.0% in Constant Currency – – Company Posts GAAP Diluted EPS of $2.50, Non-GAAP Diluted EPS of $2.86 – MARLBOROUGH, Mass.-(BUSINESS WIRE)-January 27, 2021-Hologic, I

COURTESY COPY

2021 Notice of Annual Meeting of Stockholders and Proxy Statement Thursday | March 11, 2021 | 8:00am ETOurPURPOSE Toempowerpeopletolive healthierliveseverywhere,everyday DrivenbyaPASSIONto betheleadinginnovatorinwomen’shealth.

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant  ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX:  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule

Financial Statements and Exhibits, Results of Operations and Financial Condition - HOLOGIC, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2021 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numbe

Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021

EX-99.1 2 a52358343ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021 – Revenue of $1,609.8 Million Grows 89.3%, 86.5% in Constant Currency – – Excluding Acquisitions and Divestitures, Organic Revenue More than Doubles – – Company Announces New $1.0 Billion Share Repurchase Authorization, Pays Off Revolving Debt – MARLBOROUGH, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36

Subsidiaries of Hologic.

Exhibit 21.1 Subsidiaries of Hologic Jurisdiction of Incorporation or Organization Acessa Health Inc. Delaware Beijing Hologic Technology Co., Ltd. China Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. Portugal BioLucent, LLC Delaware Bioptics, Inc. Arizona Cytyc Cayman Limited Cayman Islands Cytyc Corporation Delaware Cytyc Prenatal Products Corp. Delaware Cytyc Surgical Products, LLC

Severance and Change of Control Agreement by and between Hologic, Inc. and Sean S. Daugherty, dated August 31, 2020

EX-10.39 2 holxq4-2020ex1039.htm EX-10.39 Ex.10.39 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Sean S. Daugherty (the "Executive"), dated as of August 31, 2020. WHEREAS, the Executive has been appointed to serve as Group President, Breast and Skeletal Health and GYN Surgical, of the Company, effecti

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation) (Commission File Number

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow) (adopted fiscal 2021)

EX-10.3 Exhibit 10.3 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHARES GRANTED performance stoc

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC – Outside US) (adopted fiscal 2021).

EX-10.4 Exhibit 10.4 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHARES GRANTED performance stoc

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2021).

EX-10.6 Exhibit 10.6 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHARES GRANTED performance stoc

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR – Outside US) (adopted fiscal 2021).

EX-10.5 6 d36462dex105.htm EX-10.5 Exhibit 10.5 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (relative TSR) (adopted fiscal 2021).

EX-10.2 3 d36462dex102.htm EX-10.2 Exhibit 10.2 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Form of Performance Stock Unit Award Agreement Under 2008 Equity Incentive Plan (ROIC) (adopted fiscal 2021).

EX-10.1 2 d36462dex101.htm EX-10.1 Exhibit 10.1 Notice of Grant of Performance Stock Units and Performance Stock Unit Award Agreement Hologic, Inc. ID: 04-2902449 250 Campus Drive Marlborough, MA 01752 Grantee Name Plan: 2008 Equity Incentive Plan, as amended and restated (the “Plan”) Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHAR

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020 — Revenue of $1.347 Billion Increases 55.6%, 54.2% in Constant Currency — — Organic Revenue Increases 72.5%, 70.9% in Constant Currency, as Strong Sales of COVID Tests Offset Declines in Other Businesses — — Company Posts GAAP Diluted EPS of $1.88, Non-GAAP Diluted EPS of $2.07 — MARLBOROUGH, Mass.-(BUSINESS WIRE)-N

Financial Statements and Exhibits, Results of Operations and Financial Condition - HOLOGIC, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Numb

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Numbe

Amendment No. 2 to Amended and Restated Employment Agreement by and between the Company and Stephen P. MacMillan, dated October 5, 2020.

EX-10.1 2 d25481dex101.htm EX-10.1 Exhibit 10.1 Amendment No. 2 to Amended and Restated Employment Agreement THIS AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of October 5, 2020, by and between Hologic, Inc., a Delaware corporation (the “Company”), and Stephen P. MacMillan (the “Executive” and, together with the Company, the “Parties”)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 HOLOGIC, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Num

Indenture, dated September 28, 2020, by and among Hologic, Inc., the guarantors party thereto and Wells Fargo Bank, National Association, as Trustee

EX-4.1 2 d942100dex41.htm EX-4.1 Exhibit 4.1 HOLOGIC, INC. 3.250% Senior Notes due 2029 INDENTURE Dated as of September 28, 2020 WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 28 Section 1.03. Rules of Construction 29 ARTICLE 2 THE NOTES Section 2.01. Form, D

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 15, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Numb

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Num

Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029

EX-99.1 Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029 MARLBOROUGH, Mass., September 14, 2020 — Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000. The 2029 notes will be unsecured obligations

Severance and Change of Control Agreement dated September 15, 2020 by and between Kevin R. Thornal and Hologic, Inc.

EX-10.1 2 a8-kxthornalex101xcica.htm EXHIBIT 10.1 Exhibit 10.1 SEVERANCE AND CHANGE OF CONTROL AGREEMENT CHANGE OF CONTROL AGREEMENT by and between HOLOGIC, INC., a Delaware corporation (the "Company"), and Kevin R. Thornal (the "Executive"), dated as of September 15, 2020. WHEREAS, the Executive serves as a senior executive of the Company; WHEREAS, the Board of Directors of the Company (the "Boar

Hologic Announces Offering of $950 Million of Senior Notes Due 2029 — Proceeds from Offering Will Be Used to Refinance Existing 4.375% Senior Unsecured Notes Due 2025 —

EX-99.1 2 d87328dex991.htm EX-99.1 Exhibit 99.1 Hologic Announces Offering of $950 Million of Senior Notes Due 2029 — Proceeds from Offering Will Be Used to Refinance Existing 4.375% Senior Unsecured Notes Due 2025 — MARLBOROUGH, Mass., September 14, 2020 — Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Num

Regulation FD Disclosure - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Numb

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number)

Retirement and Separation Agreement by and between Hologic, Inc. and Peter J. Valenti, III, dated August 25, 2020

EX-10.1 2 d901581dex101.htm EX-10.1 Exhibit 10.1 RETIREMENT AND SEPARATION AGREEMENT AGREEMENT entered into as of this 25th day of August, 2020 by and between Hologic, Inc., a Delaware corporation with its principal place of business at 250 Campus Drive, Massachusetts 01752 (the “Company”), and Peter J. Valenti, III an individual having his principal residence in Connecticut (the “Executive”). WHE

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 27, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, INC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Hologic Announces Financial Results for Third Quarter of Fiscal 2020

EX-99.1 2 a52257438ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2020 — Revenue of $822.9 Million Declines 3.5% due to Cynosure Divestiture, 3.1% in Constant Currency — — Organic Revenue Increases 7.7%, 8.1% in Constant Currency, as Strong Sales of COVID Tests Offset Declines in Other Businesses — — Company Posts GAAP Diluted EPS of $0.53, Non-

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (I

- SD

SD 1 a2020formsd-conflictminera.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Hologic, Inc. (Exact name of registrant as specified in its charter) Delaware 1-36214 04-2902449 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification Number) 250 Campus Drive Marlborou

Hologic, Inc. Conflict Minerals Report

EX-1.01 2 a2020conflictminerals-exhi.htm EXHIBIT 1.01 Exhibit 1.01 Hologic, Inc. Conflict Minerals Report INTRODUCTION This Conflict Minerals Report (CMR) of Hologic, Inc. (Hologic, our, we or the Company) has been prepared pursuant to Rule 13p-1 and Form SD promulgated under the Securities Exchange Act of 1934 for the reporting period from January 1, 2019 to December 31, 2019 (the Reporting Perio

Hologic Announces Financial Results for Second Quarter of Fiscal 2020

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2020 – Revenue of $756.1 Million Declines 7.6% due to Cynosure Divestiture, 7.1% in Constant Currency – – Organic Revenue Increases 0.5%, 1.1% in Constant Currency – – Company Posts GAAP Diluted EPS of $0.36, Non-GAAP Diluted EPS of $0.57 – – Company to Introduce Second High-Throughput Coronavirus Test for Panther® Platf

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 28, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC, IN

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number

Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)

Exhibit 99.2 Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2) - Company to Produce at Least One Million Tests a Week to Run on More than 1,000 Panther Instruments Installed in All 50 States - - Significant Assay Manufacturing Capacity Plus Large Installed Base of Fully Automated Systems Expected to Dramatically Increase Coronavirus Testing Capa

Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic

Exhibit 99.1 Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic - Revenue of $756.1 Million Declines 7.6% due to Cynosure Divestiture, 7.1% in Constant Currency - - Excluding Acquisitions and Divestitures, Revenue Increases 0.5%, 1.1% in Constant Currency - MARLBOROUGH, Mass.-(BUSINESS WIRE)-April 7, 2020-Holo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number)

Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization

EX-99.1 2 a52189764ex991.htm EXHIBIT 99.1 Exhibit 99.1 Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization - New Test Will be Widely Available on Hologic’s Fully Automated Panther Fusion® System, Significantly Adding to Testing Capacity - - Only High-Throughput System to Enable Simultaneous Testing for SARS-CoV-2 and Other Common Respiratory Vir

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Number

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2020 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 1-36214 04-2902449 (Commission File Number) (

HOLX / Hologic, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Hologic Inc Title of Class of Securities: Common Stock CUSIP Number: 436440101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

HOLX / Hologic, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 28, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 HOLOGIC,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 28, 2019 HOLOGIC, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36214 04-2902449 (Commission File Num